D.E. Shaw & Co’s Envoy Medical Warrant COCHW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.53K Hold
113,431
﹤0.01% 4427
2025
Q4
$4.38K Hold
113,431
﹤0.01% 4530
2025
Q3
$4.26K Hold
113,431
﹤0.01% 4488
2025
Q2
$5.5K Hold
113,431
﹤0.01% 4268
2025
Q1
$3.74K Hold
113,431
﹤0.01% 4167
2024
Q4
$5.52K Hold
113,431
﹤0.01% 4301
2024
Q3
$10.6K Hold
113,431
﹤0.01% 4383
2024
Q2
$5.71K Hold
113,431
﹤0.01% 4355
2024
Q1
$11.9K Hold
113,431
﹤0.01% 4159
2023
Q4
$2.27K Hold
113,431
﹤0.01% 4222
2023
Q3
$9.64K Hold
113,431
﹤0.01% 4064
2023
Q2
$4.76K Hold
113,431
﹤0.01% 4113
2023
Q1
$4.33K Hold
113,431
﹤0.01% 4320
2022
Q4
$4.31K Hold
113,431
﹤0.01% 4698
2022
Q3
$4K Hold
113,431
﹤0.01% 5043
2022
Q2
$14K Hold
113,431
﹤0.01% 5084
2022
Q1
$27K Hold
113,431
﹤0.01% 5290
2021
Q4
$88K Hold
113,431
﹤0.01% 5092
2021
Q3
$71K Buy
113,431
+80,098
+240% +$65.1K ﹤0.01% 4773
2021
Q2
$32K Buy
+33,333
New +$23.8K ﹤0.01% 4660

Other funds holding COCHW

D.E. Shaw & Co's COCHW Position: Q1 2026 in Review

D.E. Shaw & Co held its Envoy Medical Warrant (COCHW) position steady in Q1 2026 at 113,431 shares worth $7.53K. The position accounts for ﹤0.01% of the portfolio, ranked #4427.

D.E. Shaw & Co first reported a position in COCHW in Q2 2021 and has held it in 20 quarters since. The position peaked at $88K in Q4 2021. 34 funds tracked by Wall St. Rank hold COCHW as of Q1 2026.

  • D.E. Shaw & Co held 113,431 shares of Envoy Medical Warrant worth $7.53K as of Q1 2026.
  • D.E. Shaw & Co left its Envoy Medical Warrant share count unchanged in Q1 2026.
  • Envoy Medical Warrant made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #4427 holding.
  • D.E. Shaw & Co first reported a position in Envoy Medical Warrant in Q2 2021 and has held it in 20 quarters since.
  • D.E. Shaw & Co's Envoy Medical Warrant position peaked at $88K in Q4 2021.
  • 34 funds tracked by Wall St. Rank held Envoy Medical Warrant as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.